(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 June 2020 (18.06.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/120730 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61K 47/26* (2006.01)
A61K 47/18 (2017.01) *A61K 9/19* (2006.01)

(21) International Application Number:
PCT/EP2019/085049

(22) International Filing Date:
13 December 2019 (13.12.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
18212591.4 14 December 2018 (14.12.2018) EP

(71) Applicant: **MORPHOSYS AG** [DE/DE]; Semmelweis-strasse 7, 82152 Planegg (DE).

(72) Inventors: **BROCKS, Bodo**; Sonnenstraße 65, 82205 Gilching (DE). **KELLERER, Robert**; Gabes 18, 85283 Wolnzach (DE).

(74) Agent: **HUTTER, Bernd**; MORPHOSYS AG, Semmelweisstr. 7, 82152 Planegg (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

WO 2020/120730 A1

(54) **Title:** ANTIBODY FORMULATIONS

Figure 1

API							
MOR202	50 g/L	50 g/L	50 g/L	75g/L	75g/L	75 g/L	75g/L
Excipients							
Citric Acid Anhydrous	0.450 g/L	0.323g/L	0.203g/L	0.323g/L	0.323g/L		
Sodium Citrate Dihydrate	2.252 g/L	2.447g/L	2.631g/L	2.447g/L	2.447g/L		
NaCl					3.0g/L		
L-Histidine						1.552 g/L	1.552g/L
HCl						q.s. to pH 6.0±0.1	q.s. to pH 5.5±0.1
pH	5.7±0.1	6.0±0.1	6.3±0.1	6.0±0.1	6.0±0.1	6.0±0.1	5.5±0.1

(57) **Abstract:** The present disclosure relates to formulations of a pharmaceutically active antigen binding protein, such as a monoclonal antibody. In particular, the present disclosure relates to a stable lyophilized pharmaceutical formulation of an anti-CD38 antibody, a reconstituted liquid formulation of such lyophilized formulation, and to methods of making and using such lyophilized and reconstituted formulations.

[Continued on next page]

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*